title: [New oral anticoagulants in the treatment of venous thromboembolic disease].
abstract: Rivaroxaban is a direct inhibitor of activated factor X, and dabigatran is a direct inhibitor of thrombin. These new oral anticoagulants have demonstrated to be effective and safe in clinical trials on the treatment of venous thromboembolic disease (deep vein thrombosis and pulmonary thromboembolism).
authors.affiliation: Servicio de Medicina Interna, Hospital Ciudad de Coria, Coria, Cáceres, España. jm.calvo@orangemail.es
authors.forename: J M
authors.initials: JM
authors.lastname: Calvo Romero
authors.forename: E M
authors.initials: EM
authors.lastname: Lima Rodríguez
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use*; D054556:Venous Thromboembolism / Q000188:drug therapy*; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; D000069552:Rivaroxaban; D000069604:Dabigatran